Assisted dying: All you need to know following the crunch Commons vote

The assisted dying Bill cleared the House of Commons in a historic vote on Friday, with MPs backing moves to legalise it by a slim majority.
Here, the PA news agency takes a look at the Bill and what happens next after a significant moment in its journey to become law.
– What is in the Terminally Ill Adults (End of Life) Bill?
The proposed legislation would allow terminally ill adults in England and Wales, with fewer than six months to live, to apply for an assisted death.
This would be subject to approval by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist.
The terminally ill person would take an approved substance, provided by a doctor but administered only by the person themselves.
On Friday, MPs voted 314 to 291, majority 23, in favour of legalising assisted dying as they completed the mainstay of their work on the Bill.
It will now face further debate in the House of Lords.
– When would assisted dying be available if the Bill became law?
The implementation period has been doubled to a maximum of four years from royal assent, the point it is rubber stamped into law, rather than the initially suggested two years.
If the Bill was to pass later this year that would mean it might not be until 2029, potentially coinciding with the end of this Government's parliament, that assisted dying was being offered.
Labour MP Kim Leadbeater, who is the parliamentarian behind the Bill and put forward the extended timeframe, has insisted it is 'a backstop' rather than a target, as she pledged to 'hold the Government's feet to the fire' on implementing legislation should the Bill pass.
The extended implementation period was one of a number of changes made since the Bill was first introduced to the Commons back in October.
– What other changes have there been?
On Friday, MPs bolstered the Bill so people with eating disorders are ruled out of falling into its scope.
Another amendment, requiring ministers to report within a year of the Bill passing on how assisted dying could affect palliative care, was also approved by MPs.
Previously, a High Court safeguard was dropped, with the oversight of judges in the assisted dying process replaced with expert panels.
The change was much criticised by opponents, who said it weakened the Bill, but Ms Leadbeater has argued it strengthens it.
At the end of a weeks-long committee process earlier this year to amend the Bill, Ms Leadbeater said rather than removing judges from the process, 'we are adding the expertise and experience of psychiatrists and social workers to provide extra protections in the areas of assessing mental capacity and detecting coercion while retaining judicial oversight'.
Changes were also made to ensure the establishment of independent advocates to support people with learning disabilities, autism or mental health conditions and to set up a disability advisory board to advise on legal implementation and impact on disabled people.
Amendments added earlier this month during report stage in the Commons will also see assisted dying adverts banned if the Bill becomes law, and a prohibition on medics being able to speak to under-18s about assisted dying.
– Do we know much more about the potential impact of such a service coming in?
A Government impact assessment, published earlier this month, estimated that between 164 and 647 assisted deaths could potentially take place in the first year of the service, rising to between 1,042 and 4,559 in year 10.
The establishment of a Voluntary Assisted Dying Commissioner and three-member expert panels would cost an estimated average of between £10.9 million and £13.6 million per year, the document said.
It had 'not been possible' to estimate the overall implementation costs at this stage of the process, it added.
While noting that cutting end-of-life care costs 'is not stated as an objective of the policy', the assessment estimated that such costs could be reduced by as much as an estimated £10 million in the first year and almost £60 million after 10 years.
– Do healthcare staff have to take part in assisted dying?
It was already the case that doctors would not have to take part, but MPs have since voted to insert a new clause into the Bill extending that to anyone.
The wording means 'no person', including social care workers and pharmacists, is obliged to take part in assisted dying and can now opt out.
Amendments to the Bill were debated on care homes and hospices also being able to opt out but these were not voted on.
Ms Leadbeater has previously said there is nothing in the Bill to say they have to, nor is there anything to say they do not have to, adding on the Parliament Matters podcast that this is 'the best position to be in' and that nobody should be 'dictating to hospices what they do and don't do around assisted dying'.
– What will happen next?
Friday's vote in the Commons makes it more likely for the assisted dying Bill to become law, now that it has the backing of a majority of MPs.
But this is not guaranteed, and first it must continue on a journey through Parliament.
The Bill now heads to the House of Lords, as both Houses of Parliament must agree its final text before it can be signed into law.
During the next stages, peers are expected to put forward amendments to the Bill. If the Commons disagrees with these amendments, this will spark a process known as 'ping pong' which will continue until both Houses agree over its text.
– Will the Bill definitely become law?
There is a risk that the Bill could be stuck in a deadlock between the House of Commons and House of Lords, as it goes back and forth in disagreement.
If this continues until the current session of Parliament ends, then the Bill would fall.
Ms Leadbeater told journalists on Friday she hoped there were no attempts to purposefully wreck it by peers.
'I really hope there are no funny games, because the process has been extremely fair,' she said.
The Spen Valley MP said she did not know when the current parliamentary session would end, but suggested it could stretch into late 2025, giving her Bill the best part of six months to complete the full parliamentary process.
Speaking about the end of the session to reporters, Ms Leadbeater said: 'I am not imagining that is going to be imminently, but it could be before the end of the year.'
One member of the House of Lords, Bishop of London Dame Sarah Mullally, has already indicated she is against it.
The Church of England bishop said peers 'must oppose' the assisted dying Bill when it reaches them because of the 'mounting evidence that it is unworkable and unsafe'.
– What about assisted dying in the rest of the UK and Crown Dependencies?
The Isle of Man looks likely to become the first part of the British Isles to legalise assisted dying, after its proposed legislation passed through a final vote of the parliament's upper chamber in March.
In what was hailed a 'landmark moment', members of the Scottish Parliament (MSPs) in May voted in favour of the Assisted Dying for Terminally Ill Adults (Scotland) Bill, backing its general principles.
It will now go forward for further scrutiny and amendments but will become law only if MSPs approve it in a final vote, which should take place later this year.
Any move to legalise assisted dying in Northern Ireland would have to be passed by politicians in the devolved Assembly at Stormont.
Jersey's parliament is expected to debate a draft law for an assisted dying service on the island for terminally ill people later this year.
With a likely 18-month implementation period if a law is approved, the earliest it could come into effect would be summer 2027.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Boston Globe

35 minutes ago

• Boston Globe

UK lawmakers approve assisted-dying law

Advertisement 'I do not underestimate the significance of this day,' Kim Leadbeater, a Labour Party lawmaker and main champion of the bill, said Friday as she opened the debate. 'This is not a choice for living and dying. It is a choice for terminally ill people about how they die.' While assisted dying is illegal in most countries, a growing number of nations and jurisdictions have adopted legislation or are considering it. In England and Wales, assisting a death remains illegal and punishable by up to 14 years in prison. A poll published this week found that 73 percent of Britons backed the assisted-dying bill. While lawmakers voted in favor of the bill in November, at an earlier stage in the legislative process, uncertainty lingered ahead of Friday's vote. Hundreds of demonstrators on both sides gathered outside Parliament. Some carried placards that read, 'Let Us Choose.' Others held signs saying, 'Don't make doctors killers.' Advertisement Many of those who spoke during the debate shared personal stories. Mark Garnier, a Conservative Party politician, spoke about witnessing the dying days of his mother, who had pancreatic cancer and endured a 'huge amount of pain.' Garnier compared her ordeal to that of a constituent who also had pancreatic cancer but went through a state-provided assisted-dying program in Spain that made her 'suffering much less.' Josh Babarinde, a Liberal Democrat, read out a letter from a constituent traumatized by the death of her partner, who struggled to breathe, was incontinent, and repeatedly asked for her help to end his life. He then 'stuffed yards of his top sheet into his mouth' in an attempt to die,' Babarinde said, adding: 'This could have been avoided with an assisted-dying' law. Support for the measure ebbed in recent months, with a handful of politicians saying that they were going to switch their vote due to concerns about inadequate safeguards or insufficient end-of-life care. Steve Darling, a Liberal Democrat, told The Washington Post that while he was 'sympathetic' to the bill, he had changed his view because of 'inadequate' palliative care funding, which in Britain depends heavily on charitable donations. 'People might think, 'I could bite the bullet and get out of this situation because I'm not receiving a service that gives me a decent quality of life toward the end,'' Darling said. Others who said they agreed with the principle of letting people choose to die but could not back the bill included Labour member Vicky Foxcroft, who cited her work with disabled people. 'They want us as parliamentarians to assist them to live, not to die,' Foxcroft told Parliament. Advertisement The issue remains divisive even within parties. Health Secretary Wes Streeting and Justice Secretary Shabana Mahmood, whose departments will each be impacted if the change becomes law, both opposed the bill. Prime Minister Keir Starmer made it clear that he supports the measure, citing his experience as the country's former chief prosecutor. Over the past two decades, more than 3,900 Britons have ended their lives with the Switzerland-based organization Dignitas. A few people who helped them were investigated or arrested. The vote Friday was a free vote, meaning that lawmakers could decide based on their own conscience rather than along party lines. It was the second time this week that Parliament held a free vote, which is often allowed on issues of ethics or conscience. Earlier this week, lawmakers voted in favor of decriminalizing abortion in England and Wales. One major revision to the bill in recent months was to eliminate the need for approval from a high court judge. No other country or jurisdiction with legalized assisted dying has that kind of stringent judicial oversight, and it was initially sold to some wavering lawmakers as a reason to back the bill. That requirement was dropped in favor of a three-person expert panel — a lawyer, social worker, and psychiatrist — that will oversee applications. Leadbeater said this would make the bill stronger, as members of the panel would have more relevant expertise and would be better able to spot red flags. Spain uses a similar kind of expert panel. Some professional bodies, such as the Royal College of Psychiatrists, remain neutral on the principle of assisted dying but opposed the legislation as written. Their concerns included the shortage of qualified staff for the expert panels. Advertisement The government's own 'impact assessment' found that the law could lead to 7,500 requests a year within a decade. Some campaigners had hoped for greater eligibility, to include patients experiencing unbearable suffering with no prospect of improvement, or allowing a doctor to administer a lethal cocktail of drugs. This bill allows assisted dying only for terminally ill patients who can administer the medication themselves. Speaking in Parliament, Peter Prinsley, a Labour lawmaker, said that 'as a young doctor, I found the measures that we're debating today completely unconscionable.' However, he added, 'now that I'm an old doctor, I feel sure this is an essential change.' 'We are not dealing with life or death, rather death or death,' Prinsley said. 'And fundamental to that is surely choice. Who are we to deny that to the dying?'

Yahoo

an hour ago

• Yahoo

Major projects bill expected to pass before MPs leave for the summer

OTTAWA — If you blink, you might miss it. Prime Minister Mark Carney's controversial major projects bill was set to finish its dash through the House of Commons today — the final day of the sitting before summer — with support from the Conservatives and not-so-quiet grumblings from the other opposition parties. 'Usually, on the last day of sitting before the summer, everyone is smiling, we're in a good mood, we pat ourselves on the backs. But today, I would say that's not really the case,' said Bloc Québécois MP Xavier Barsalou-Duval during a speech on Friday. The final vote on Bill C-5 in the House is set to happen shortly after 5 p.m. before making its way to the Senate for a final adoption expected within a week, on Friday, June 27. The legislation has two parts. The first, which has more support across party lines, aims to eliminate internal trade and labour mobility barriers in Canada. The second part, which would give cabinet sweeping powers to approve natural resource and infrastructure projects deemed in the national interest, has raised considerably more concerns. Indigenous communities, environmental groups, opposition parties and even some Liberal MPs have said they are uncomfortable with the lack of consultation with First Nations, Inuit and Metis people prior to tabling the bill, but also the extent of the powers that would give the government of the day the power to ignore other federal laws for five years. 'Pretending that this unprecedented power grab was ever discussed in the election is a sham, and we can add an 'e' to that. It's a shame,' said Green Party leader Elizabeth May. C-5 was rushed through committee earlier this week. Despite that, opposition parties managed to pass amendments which include exempting a number of laws — such as the Indian Act and the Conflict of Interest Act — from being ignored when considering major projects and publishing a list of national interest projects with timelines and costs. 'These amendments matter,' said Shannon Stubbs, energy and natural resource critic for the Conservatives when describing the changes in the House. 'They bring transparency, accountability, more certainty, more clarity and integrity to a bill that originally had none.' Stubbs said despite those changes, 'major concerns' remain. She cited the need to prevent ministers from removing projects from the national interest list at any time but also add in the bill clear timelines to approve projects to increase certainty for investors. On Friday, opposition parties claimed a small victory. NDP MP Jenny Kwan, with the help of the Bloc's Marilène Gill, argued the Speaker of the House should divide C-5 into two distinct parts so that MPs could vote on the portions on internal trade and major projects separately at third reading. Speaker Francis Scarpaleggia granted their request. 'While they are ultimately designed to strengthen the Canadian economy, they deal with different issues that could very well stand independently from one another,' he explained. The passage of C-5 concludes in a dramatic way a packed four-week spring sitting that saw Carney's government table significant omnibus bills, very fast, but adopt very few. The government tabled C-2, the Strong Borders Act, which seeks to secure the Canada-U.S. border, fight organized crime and fentanyl and boost the fight against financial crimes. It is facing criticism for sweeping new powers that would allow officials to obtain information without a warrant and for restricting the asylum claim process, among others. It also tabled C-4, the Making Life More Affordable for Canadians Act, which includes some of the government's campaign promises on affordability like a middle-class tax cut and removal of the GST on new homes for first-time homebuyers. However, the bill has been criticized as it also seeks to exempt federal political parties from modern privacy laws. Unlike the major projects bill, C-2 and C-4 were not fast-tracked, meaning that they will continue to make their way through the legislative process during the fall sitting. Interestingly, the first legislation to pass all stages in this new Parliament was not a government bill. Last week, MPs unanimously approved C-202, a Bloc bill to protect the supply management system which regulates the price and production of dairy, poultry and eggs, from future trade deals. That same bill was stalled in the Senate in the last legislature and ended up dying on the order paper when the election was called. This time, the Senate approved C-202 on division, and it is now awaiting royal assent. National Post calevesque@ Doug Ford apologizes to Ontario First Nations for his 'passionate' comments 'We have to get that balance right': Liberal MPs express worries about major projects bill Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.

Medscape

an hour ago

• Medscape

Jun 20 2025 This Week in Cardiology

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast , download the Medscape app or subscribe on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only. In This Week's Podcast For the week ending June 20, 2025, John Mandrola, MD, comments on the following topics: a big, deep dive into CTA and fractional flow reserve CT, and a sobering report on the new EVOQUE valve. Mark Petrie from the UK writes to correct my description of the CRAAFT-HF trial. I mistakenly said it was a surgical vs catheter ablation trial, but Dr Petrie said that they were actually randomizing to atrial fibrillation (AF) ablation plus heart failure with reduced ejection fraction (HFrEF) medical therapy vs HFrEF medical therapy alone in patients with left ventricular dysfunction. Saturday is the first day of summer. Where has the time gone? There is a spot at the halfway point of our 5 AM ride, about 20 miles out in the country that the sun rises over a farm on a hill. It's a hot spot on the ride but once a year I try to convince the crew to stop for a photo. Imaging and Behavior Change Five Reasons I Don't Believe an Imaging Test Improves Outcomes My friends in Edinburgh, who have been leaders in the use of coronary computed tomographic angiography (CCTA), report on a nested substudy within the SCOT-HEART 2 trial. Let's start with SCOT-HEART 1, which randomized symptomatic patients (stable CP) to receive CTA plus standard care vs standard care alone — which often included functional stress testing. CCTA-led care led to a significantly lower rate of death from cardiovascular (CV) death and nonfatal myocardial infarction (2.3 vs 3.9%). This seemed like a big win for CCTA, but the controversy centered on the fact that the small delta in statin use in the two groups (more in the CTA) was nowhere near enough to drive the large reduction in myocardial infarction (MI). For instance, I cited Andrew Foy, who calculated that to believe statin therapy drove SCOT-HEART, you'd have to believe statins have a number needed to treat (NNT) of 3, not its normal 50-100. Nonetheless, the use of CCTA is different in cost-constrained systems like Scotland. In Scotland, it is used to reduce coronary angiography and PCI. Knowledge of coronary artery disease (CAD) is used to guide medical therapy, and there is no incentive to do more angiography. In the United States, CCTA is used as a cash machine, because the nanosecond an American patient and American doctor see CAD, the patient gets a hotline to the cath lab and PCI. The problem, of course, with anatomical testing is that you can have twinge of chest pain from a cramp and if you have incidental CAD, boom, you now have lifelong dependence on antiplatelet. Now to the SCOT-HEART 2 trial, which is a randomized controlled trial (RCT) using CTA. The study question is this: Is screening with CTA more clinically effective than CV risk scoring with an equation? The plan is to enroll at least 6000 people (not patients, people ) in Scotland who are at risk of heart disease to CTA-guided management vs equation-guided management. They will use an equation called ASSIGN, which is like the pooled cohort equation (it only uses outcome data from Scotland) and includes the social deprivation score. Those in the equation (or standard care) arm get lifestyle advice and lipid-lowering therapy (LLT) for 10-year risk > 10%. Those in the CTA arm get lifestyle advice for normal CTA, lifestyle advice, plus LLT and aspiring for non-obstructive disease, and for those with obstructive disease, they get lifestyle advice, LLT, aspirin, ACE inhibitor plus review by a cardiologist. At 5 years, the primary outcome is coronary death or MI. There are lots of secondary outcomes. JAMA Cardiology has published a nested cohort study within SCOT-HEART 2 looking at a primary outcome of the proportion of participants who achieved the National Institute for Health and Care Excellence (NICE) recommendations for diet, BMI, smoking and exercise. Diet, smoking and exercise were self-reported, and weight, BMI, and step count were measured. The study population included 400 people enrolled over 4 years, which does not seem like a lot. At 6 months, those in the CTA screening were more likely to meet the primary composite endpoint of compliance with the NICE recommendations for diet, BMI, smoking and exercise — it was 17% vs 6%. These seem low but that's because people had to reach all four of the components. The relative risk increase was an odds ratio of 3.4 times more likely to achieve these four goals in the CTA group. Other secondary findings were that fewer participants in the CTA group were recommended for LLT (51% vs 75%). That's because the risk score placed more above 10% but with normal CTA, LLT was not given. Even though fewer LLTs were recommended with CTA, acceptance of LLT was higher in the CTA group, 77% vs 46%. In the end, statistically similar numbers of patients took LLT in both groups (44% vs 35%). Antiplatelet use was much higher in the CTA group, 40% vs 0.5%. The authors broke down secondary outcomes based on whether CTA showed disease, and this associated with slightly lower weight, BMI, waist circumference, blood pressure, total and LDL cholesterol concentrations, and greater improvements in daily step count. Another interesting twist was that 100 individuals in the CTA arm were given a verbal report of their CTA and the 100 were shown their images. No differences were seen in the two subgroups for the primary and secondary outcomes. The authors were pretty calm in their conclusions. They note these interesting observations, that CTA resulted in more accurate risk stratification where some patients with high equation risk had no disease and some patients with low equation risk had disease. CTA did increase acceptance of lipid-lowering therapy as well as increase the proportion of patients reaching lifestyle goals. The obvious take-home message here is that this data supports the seeing-is-believing idea. The editorialists wrote enthusiastically that: 'the results of this nested randomized clinical trial within the SCOT-HEART 2 study are striking. A preventive strategy incorporating CCTA appeared to be not only more precise but also more motivating to participants and clinicians. CCTA reclassified 1 in 3 individuals based on 10-year risk score, targeting therapy to those who were assumed to derive greatest benefit.' I laud the Edinburgh team for doing SCOT-HEART 2. But the differences in verbal acceptance of lifestyle, or LLT use, or aspirin use, or tiny blood pressure (BP) changes are not what we care about. The only outcome is MI or coronary death. When you submit a person with no disease to medical imaging, it ought not be for motivation. It should only be for their health benefit. The changes in lifestyle or drug use or more precise risk stratification are made up surrogate endpoints that have meaning only if there is a difference in outcomes. I strongly oppose the use of imaging to scare patients into taking statins or not eating chips. In Scotland, the downstream effects of CTA may be different than in the US. Here, it is highly likely that seeing disease will affect future interventions. Let's say there is mild disease noted on a screening CTA. Maybe the US patient is given statins and aspirin. Well, what do you think happens in the months or years to come the next time that patient has a twinge of CP? It's right to the ER and then the cath lab for stents or bypass. We need to celebrate the fact that SCOT-HEART 2 will be done, but until then, we need to resist the urge to image our patients based on minor differences in surrogate endpoints, some of which are self-reported. Heart disease treatment and prevention is simple: it's lifestyle (including diet and exercise), possibly lipid-lowering therapy. Imaging is not required and should not be done until there is evidence it improves outcomes. Symptoms Don't Always Indicate the Severity of Coronary Artery Disease JACC-CV Interventions has published a research letter looking at the association between cardiac symptoms and coronary plaque. I will call this a back-to-the-future study with modern imaging confirming a lesson that Dr Bernard Lown described a half-century ago Only now we get to toss around terms like fractional flow reserve, total plaque atheroma, and — sit down for this one — artificial intelligence–enabled quantitative coronary plaque analysis (AI-QCPA) tools. I will speak about the letter, which is modest, but the main thing that happened is that it caused me to look into the FFR-CT data. And OMG. The researchers used data from the ADVANCE registry, which was a 5000-patient registry from multiple centers done to assess how often FFR-CT changes management vs regular CT. The sample included about 4300 patients who referred for coronary CT and had a coronary lesion. Symptoms were characterized by a) squeezing chest or neck pain, b) pain precipitated by exertion, c) relieved by nitrates or rest. Typical angina had all three; atypical angina had 2 of 3, noncardiac had one, and there was also a group with dyspnea only. There were five groups of patients: 25% no symptoms 10% dyspnea only 6% noncardiac 37% atypical chest pain 22% typical angina Now pause. The authors had total plaque volume and FFR-CT on each of these patients. Then they just did correlations. And they found, with these correlations: Only typical angina had a positive correlation with plaque atheroma. Typical angina also correlated strongly with negative values of FFR-CT. The authors also noted, surprisingly, that atypical chest pain, noncardiac chest pain, and dyspnea each correlated with higher FFR-CT, greater than 0.8 suggestive of normal flow. The authors and imaging proponents seem excited about this. In a Medscape news article, one of the authors says: 'Even having no symptoms was not a reliable indicator of cardiovascular health in these patients. Just because a patient doesn't report any symptoms doesn't mean there is no atherosclerosis.' Also quoted in the news article, Matthew Budoff, MD, a cardiologist at UCLA said: 'cardiologists rely heavily on symptoms to determine how severe cardiovascular disease is, but the new research is beginning to dispel that idea.' Budoff also added that: 'the new findings support the idea CT angiography should be a bigger part of the diagnostic process, so clinicians can look not only at whether a patient has stenosis but also go beyond to see if they have any atherosclerosis or plaque that might be a target for medical therapy.' This letter seems so funny to me. One of the first lessons we were taught at Indiana University in the 1990s was that when a patient presented with typical angina and even a positive stress test, that catheterization would show left main or severe triple vessel disease about 10%, it would be normal in 10%, and somewhere in between in 80%. In other words, symptoms are a very unreliable marker of CAD. Now we have a study that uses have artificial intelligence (AI), CT, FFR, and multivariable regression to confirm something that's as old as the hills. I don't agree with Dr Budoff that cardiologists rely heavily on symptoms. At least not in many places in the US. The main requirement for a stress test in the US is insurance coverage and the main requirement for a cath is a wrist. We don't rely on symptoms. We rely on imaging and angiography. I have this saying that I don't say too much anymore but think often: If every stress imaging machine broke for a month, heart disease outcomes would not change. I wonder whether this also applies to CTA imaging and surely to FFR-CT. A colleague tells me that FFR-CT adds $1500 to basic CTA. I find that shocking. Now I want to go to the advance registry paper in 2018. The main value in this research letter was a kick in the butt to go back to the original evidence for this FFR-CT business, the publication of the ADVANCE registry in the European Heart Journal in 2018. First author Fairbairn. This will be a trigger warning because this is one of those things you can't unsee or unhear. ADVANCE registry included about 5000 patients with symptoms concerning for CAD and atherosclerosis on CCTA. The authors recorded the basic info, symptoms, CCTA and FFR-CT findings were recorded along with treatment plans. They also had 90-day outcomes. For each enrolled patient, a clinical management review committee used data from coronary CTA to determine the management plan using the following criteria: (a) optimal medical therapy, (b) percutaneous coronary intervention (PCI), (c) coronary artery bypass graft surgery (CABG), or (d) more information required. The primary endpoint of the registry is the reclassification rate between the management plan based on coronary CTA alone vs CTA plus FFR-CT. Two teams came up with the original plan based only on CTA. A site team and a blinded core team from Duke. The primary endpoint was the reclassification of the treatment plan from the CT-FFR results. The primary results were that it changed management in about two-thirds of the cases. It was hard for me to see a pattern in the reclassification. The authors tell us later that the majority of subjects were safely deferred to medical management alone, and only a minority required 'further testing.' A second finding was that rate of no significant disease at angiography was significantly lower in patients who had a positive FFR < 0.8 (about 15%) vs > 0.8 (44%). Odds ratio for no significant disease was 0.19 for a positive FFR (that is < 0.8) A third finding was that 19 MACE events happened in the 90 days after the study, 10 of them were death, and all happened in the FFR < 0.8 category — 19 vs 0. The authors concluded that FFR-CT was great. It guided management, helped predict no disease, and even had a strong association with MACE events. They noted this: 'FFR-CT led to a recommendation of invasive coronary angiography (ICA) in only 40% of subjects in a cohort with an anatomic obstructive disease rate of 72%, and subjects referred for ICA downstream were significantly more likely to have obstructive disease at ICA if they had a positive FFR-CT.' And this: 'Importantly, a negative FFR-CT was associated with an excellent short-term prognosis, as none of the 1600 subjects with negative FFR-CT experienced death, MI, or unplanned hospitalization for ACS and urgent revascularization.' A colleague in imaging advises me that this was one of the major studies cited to establish FFR-CT. My gosh, this is terrible. What a mess. First of all, the study was sponsored by HeartFlow. It was a late-breaker at ESC in 2018. I must have had jet lag because I missed it. Much of my criticism follows a Twitter thread from my friend Venk Murthy at University of Michigan. A primary endpoint in change in management in a voluntary registry sponsored by the company is about as weak an endpoint as you can get. Why isn't this a measurement of clinical psychology? What if you chose, say, in a non-industry-funded study, a doctor team skeptical of FFR-CT. I bet few would be swayed by the CT-FFR results. Another problem was that most of the FFR-CT values were abnormal in the left anterior descending artery (LAD) and were between 0.7-0.85. We know this from the IQR values. But now I will cite a study from Christopher Cook in Darrell Francis' group published in JAMA Cardiology 2017. What this London group found is that when doing a systematic review of all studies measuring the diagnostic accuracy of FFR-CT, they found that values just under the cutoff of 0.8 (that is, between 0.7 and 0.8) had the lowest accuracy — only 46% accurate. Pause there. That's like a coin flip. Cook et al report that if you want accuracy from FFR-CT, say 82% overall accuracy threshold, you needed values lower than 0.63 or above 0.83. And if you wanted more stringent 95% and 98% diagnostic accuracy thresholds from FFR-CT, you needed values lower than 0.53 or above 0.93, and lower than 0.47 or above 0.99, respectively. A third issue is that most of the patients (77%) were nontypical angina — either atypical or non-cardiac pain. But we know from the Manesh Patel seminal NEJM paper from 2010 that when patients with atypical symptoms go to cath, the chance of obstructive disease is low — regardless of the results of stress testing. In fact, a positive stress test only changed the likelihood of having CAD from 35% to 41%; hence, my stance that if every stress imaging machine broke, CV outcomes would hardly change. The point in citing this seminal paper is that most patients in the ADVANCE registry study — the 77% with atypical symptoms — should not have had a change in management. A fourth issue is that the MACE events are 100% noise — 19 vs 0. And 10 deaths in the first 90 days. I can't even believe they mentioned MACE events. The CI for the odds ratio goes from 1.2 to 326. The P-value, however, was calculated to be significant at .039, which is crazy. So, in sum, this is one of the weakest, late-breaking, practicing-changing trials I have seen. It's a psychology experiment and we have no idea a) which treatment strategy was best, and b) what meaning is there in changing a treatment strategy without knowing which one is correct. If we wanted to know about FFR-CT, it's simple: you randomize people to care with the HeartFlow FFR-CT vs those without. Then you measure outcomes — MI, CV deaths, even urgent revascularization. But this was not done. Instead, FDA approves the HeartFlow, proponents and key opinion leaders speak highly of it, these studies are not highly criticized, and CT scans get $1500 added to them. HeartFlow was approved de novo in 2014 but received a 2019 clearance for 'virtual modeling.' When I asked my AI friend Claude to explain the difference between the two designations — 2014 and 2019 — one of the 'significant' points was a business model expansion wherein the original FFR-CT was a one-time diagnostic test, but the 'planner (the virtual modeling) creates additional revenue opportunities for each patient who needs intervention.' And then this: the 2019 decision Expands HeartFlow's market from diagnosis into treatment planning. My AI program Claude must not know I am a critical appraiser because it then wrote: Physicians can now use HeartFlow for the entire patient journey: diagnosis → treatment planning → post-intervention assessment. This creates much stronger physician adoption and stickiness. And it makes the cost–benefit analysis more favorable since one CT scan can support multiple clinical decisions. The 2019 Planner approval was huge for HeartFlow because it transformed them from a diagnostic company into a comprehensive coronary care platform. Instead of just answering "Does this patient need a catheterization?", they can now answer: "Exactly how should we treat this patient's disease?" This is why HeartFlow's valuation and market penetration accelerated significantly after 2019. They weren't just competing with stress tests anymore; they were competing with the entire invasive workup process. I had no idea this stuff was happening. What a tragic waste of money. This may be one of the lowest value medical interventions I have seen. And you think I am wrong to be hopeful about FDA new leadership. Regulators should have required an RCT. Since they did not require and RCT, physicians should. Companies are not nefarious. They simply jump over the bar we hold for them. In this case the bar was ridiculously low. Speaking about lax FDA regulation, JACC has published a sobering research letter on the transcatheter tricuspid valve replacement called the EVOQUE valve. This one is also really scary. On this I hardly need commentary; I can just tell you the data. First author was Lior Lupu. FDA approved the valve in February 2024. This was based on the pivotal TRISCEND II trial, which was driven quality-of-life measures, not hard outcomes, and was not blinded. Thus, placebo effects were surely present. The group of authors from Washington, DC used the MAUDE database at FDA, which stands for Manufacturer and User Facility Device Experience. It contains information about device malfunctions, injuries, and deaths associated with medical devices that have been reported by manufacturers, healthcare facilities, and users. The main weakness of MAUDE is that there is no denominator and it's voluntary. In the year since approval, the research team found 150 reports on EVOQUE that describe 158 events. 1. Bradycardia or high degree atrioventricular (AV) block was most common (n = 70 or 44%) and there were 2 deaths. 66 of the 70 required pacemakers. Most were detected at the implant however a third were seen later between days 3 and 90. 2. Device malposition, migration, or embolization occurred in 33 patients (20.9%), causing 6 deaths. Most events were diagnosed within 3 months: 76% intraprocedurally, 14% within 2 days, and 7% between 3 days and 3 months. Management included transcatheter valve-in-valve implantation in 10 cases (eg, SAPIEN-in-Evoque), with 2 requiring a second valve for optimization. Two patients underwent transcatheter treatment for paravalvular leak, while 16 required surgery. 3. EVOQUE leaflet thickening or thrombus was identified in 20 patients (12.7%), with clinical or hemodynamic consequences reported in 16 of the 20. Cases were detected within the first month (56.3%), between months 2 and 6 (25.1%), and after 1 year (18.8%). Management included thrombolysis (n = 4), transcatheter valve-in-valve implantation (n = 2; 1 also had device migration), and surgery (1 patient with severe postprocedural thrombosis with hemodynamic instability). 4. Cardiac tamponade was reported in 8 patients (5.1%), with 5 patients undergoing surgery and 4 deaths. 5. Venous injury or bleeding occurred in 8 patients (5.1%), with 2 deaths. 6. Five cases of ventricular tachycardia, fibrillation, or cardiac arrest were reported: 2 intraprocedurally and 3 postprocedurally (days 0, 4, and 7). 7. Mechanical failure of the delivery catheter was reported in 4 patients (2.5%), all due to nose cone separation. The authors write that while bradycardia, tamponade, valve injury, and valve thrombosis had been reported in the trial, valve malposition, migration, or embolization — the second most frequently reported adverse event in this research letter — were not reported in the trial. So, they were new discoveries. Also, additionally, 3 cases of ventricular arrhythmia or cardiac arrest were reported within the first postprocedural week without a definite etiology. Nose cone separation wherein the nose can go missing into the PA also occurred. Like I said, I hardly need comment because the list of complications is so sobering. Of course, MAUDE has no denominator, but on the other hand it is also voluntary, so this is likely underreporting. I would note that only 237 patients received a valve in the TRISCEND II pivotal trial. There were substantial complications noted. To me, this was quite lax regulation. First, there should have been a trial with a sham procedure. Quality-of-life metrics are meaningless when one group gets a procedure and the other group gets bland white tablets. Second, there should have been more patients in the trial. And third, the approval should have been contingent on a required database, such as that with TAVR. This report is really scary given the number of deaths. In fact, mortality from tricuspid valve surgery is the main reason transcatheter techniques were designed. In the transcript, I highlighted in orange font the number of deaths. I counted 14 deaths and 5 cases of ventricular tachycardia/cardiac arrest. Proponents may cite the learning curve, but I doubt it because I read that the company did a slow rollout where centers who were part of the trial were first. And you wonder why I am a medical conservative and slow adopter.